PL2747561T3 - Leczenie objawów związanych z gastroparezą u osobników płci żeńskiej - Google Patents

Leczenie objawów związanych z gastroparezą u osobników płci żeńskiej

Info

Publication number
PL2747561T3
PL2747561T3 PL12825447T PL12825447T PL2747561T3 PL 2747561 T3 PL2747561 T3 PL 2747561T3 PL 12825447 T PL12825447 T PL 12825447T PL 12825447 T PL12825447 T PL 12825447T PL 2747561 T3 PL2747561 T3 PL 2747561T3
Authority
PL
Poland
Prior art keywords
treatment
symptoms associated
female gastroparesis
gastroparesis
female
Prior art date
Application number
PL12825447T
Other languages
English (en)
Inventor
Matthew J. D'onofrio
David A. Gonyer
Marilyn R. Carlson
Original Assignee
Evoke Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evoke Pharma, Inc. filed Critical Evoke Pharma, Inc.
Publication of PL2747561T3 publication Critical patent/PL2747561T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL12825447T 2011-08-25 2012-08-23 Leczenie objawów związanych z gastroparezą u osobników płci żeńskiej PL2747561T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161527563P 2011-08-25 2011-08-25
US201261583447P 2012-01-05 2012-01-05
PCT/US2012/052096 WO2013028882A1 (en) 2011-08-25 2012-08-23 Treatment of symptoms associated with female gastroparesis
EP12825447.1A EP2747561B1 (en) 2011-08-25 2012-08-23 Treatment of symptoms associated with female gastroparesis

Publications (1)

Publication Number Publication Date
PL2747561T3 true PL2747561T3 (pl) 2018-11-30

Family

ID=47746868

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12825447T PL2747561T3 (pl) 2011-08-25 2012-08-23 Leczenie objawów związanych z gastroparezą u osobników płci żeńskiej

Country Status (14)

Country Link
US (1) US20130217775A1 (pl)
EP (1) EP2747561B1 (pl)
JP (3) JP2014524478A (pl)
CN (1) CN103957707A (pl)
BR (1) BR112014004418A8 (pl)
CA (1) CA2846340A1 (pl)
DK (1) DK2747561T3 (pl)
ES (1) ES2683042T3 (pl)
MX (1) MX356317B (pl)
PL (1) PL2747561T3 (pl)
PT (1) PT2747561T (pl)
RU (1) RU2616520C2 (pl)
TR (1) TR201811221T4 (pl)
WO (1) WO2013028882A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
WO2018112061A1 (en) * 2016-12-15 2018-06-21 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
WO2018191584A1 (en) * 2017-04-14 2018-10-18 The Johns Hopkins University Nutritional and therapeutic supplement compositions
AU2018309667A1 (en) * 2017-07-31 2020-02-06 Alfasigma S.P.A. Methods of treating symptoms of gastroparesis using velusetrag
MX2020002682A (es) * 2017-09-11 2020-10-05 Evoke Pharma Inc Metodos de dosificacion intranasal de metoclopramida.
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281394A (pl) 1961-07-25
US4624965A (en) 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US5760086A (en) 1996-03-14 1998-06-02 Ribogene, Inc. Nasal administration of agents for treatment of delayed onset emesis
HUP9902891A3 (en) * 1997-03-13 2000-11-28 Ribogene Inc Hayward Intranasal administration of a metoclopramide containing spray for treatment of delayed onset emesis
US6187332B1 (en) * 1999-06-14 2001-02-13 Wisconsin Alumni Research Foundation Acidic buffered nasal spray
GB9918559D0 (en) * 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
US6770262B2 (en) * 2000-03-30 2004-08-03 Questcor Pharmaceuticals, Inc. Nasal administration of agents for the treatment of gastroparesis
US20030044356A1 (en) * 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US20050137265A1 (en) 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
ES2536885T3 (es) 2008-12-22 2015-05-29 Evoke Pharma, Inc. Formulaciones nasales de metoclopramida
WO2010109482A2 (en) * 2009-03-23 2010-09-30 Laila Pharmaceuticals Pvt. Ltd. Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions

Also Published As

Publication number Publication date
JP2014524478A (ja) 2014-09-22
WO2013028882A1 (en) 2013-02-28
RU2616520C2 (ru) 2017-04-17
US20130217775A1 (en) 2013-08-22
RU2014111070A (ru) 2015-09-27
TR201811221T4 (tr) 2018-08-27
BR112014004418A8 (pt) 2018-01-23
EP2747561A4 (en) 2014-12-24
JP2018008979A (ja) 2018-01-18
CA2846340A1 (en) 2013-02-28
EP2747561A1 (en) 2014-07-02
MX356317B (es) 2018-05-23
ES2683042T3 (es) 2018-09-24
PT2747561T (pt) 2018-09-28
EP2747561B1 (en) 2018-05-09
JP2019031551A (ja) 2019-02-28
DK2747561T3 (en) 2018-08-06
MX2014002125A (es) 2014-10-17
BR112014004418A2 (pt) 2017-03-28
JP6511492B2 (ja) 2019-05-15
CN103957707A (zh) 2014-07-30

Similar Documents

Publication Publication Date Title
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
EP2717855A4 (en) PROCESSING METHODS
HK1199015A1 (en) Treatment of inflammation
EP2704723A4 (en) TREATMENT OF POLYCYSTIC DISEASES
PT2747561T (pt) Tratamento de sintomas associados com a gastroparesia feminina
HK1199737A1 (en) Treatment of coal
GB201309274D0 (en) Treatment Of Fuel
IL228589A0 (en) Medical Care
GB201107467D0 (en) Novel treatment of pain
ZA201308117B (en) Avian-based treatment
GB201100455D0 (en) Methods relating to treatment
GB201121044D0 (en) Treatment of solutions
GB201110602D0 (en) Methods of treatment
GB201109737D0 (en) Methods of treatment
GB201105302D0 (en) Treatment of acidosis
IL222594A0 (en) Combined treatment utilizing vb-201
EP2696872A4 (en) TREATMENT OF GLAUCOMA
GB201111247D0 (en) Treatment
GB201109119D0 (en) Treatment
GB201102267D0 (en) Treatment
GB201102274D0 (en) Treatment
GB201102277D0 (en) Treatment
GB201102282D0 (en) Treatment
GB201102266D0 (en) Treatment
GB201102284D0 (en) Treatment